Oric Pharmaceuticals, Inc.

Kejia Wu

Xiaohui Du

Jared Moore

Hiroyuki Kawai

Daqing Sun

Liusheng Zhu

Yosup Rew

John Eksterowicz

Valeria R Fantin

Qiuping Ye

Brian Richard Blank

Tatiana Zavorotinskaya

Johnny Pham

Chien-Hung Yeh

F Anthony Romero

Stephane Ciblat

Paul Gibbons

Lea Constantineau-Forget

Joanne Tan

Jae Hyuk Chang

Chudi Ndubaku

Hong Wang

Amit Nayyar

Vincent Albert

Dilan Emine Polat

Hugo De Almeida Silva

Daniel Gordon Michael Shore

Described herein are CD73 inhibitors and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful for the treatment of cancer, infections, and neurodegenerative diseases.

CD73 inhibitors

Disclosed herein are compounds of Formula (I), or pharmaceutically acceptable salts thereof, that are inhibitors of Polo Like Kinase 4 (PLK4). Also disclosed herein are pharmaceutical compositions comprising the compounds of Formula (I), or pharmaceutically acceptable salts thereof, and one or more pharmaceutically acceptable excipients. Further disclosed herein are methods of treating cancer in a subject in need thereof, comprising administering to the subject an amount of a compound of Formula (I), or a pharmaceutically acceptable salt thereof.

Polo like kinase 4 inhibitors

Growing community of inventors

South San Francisco, CA, United States of America

Kejia Wu